SCHEMBL25846202

SCHEMBL25846202

CC(=O)[C@](C)(N)Cc1ccc(O)c(O)c1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.76
HSD17B10 Q99714 7/20 0.76
ALOX15 P16050 6/20 0.76
TDP1 Q9NUW8 5/20 0.76
MAPT P10636 5/20 0.76
HPGD P15428 5/20 0.76
ALDH1A1 P00352 5/20 0.76
BLM P54132 5/20 0.76
POLB P06746 4/20 0.76
RECQL P46063 4/20 0.76
CYP1A2 P05177 3/20 0.76
CYP3A4 P08684 3/20 0.76
USP2 O75604 3/20 0.76
PTGS2 P35354 3/20 0.76
APEX1 P27695 3/20 0.76
PMP22 Q01453 3/20 0.76
ADRA1A P35348 3/20 0.76
MTOR P42345 3/20 0.76
EGFR P00533 2/20 0.76
FYN P06241 2/20 0.76

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13431276 1.00 KDM4E (0.76) KDM4EHSD17B10ALOX15TDP1MAPT
Methyldopa (Racemic) SCHEMBL28969518 0.87 KDM4E (0.94) KDM4EHSD17B10ALOX15TDP1MAPT
Methyldopa SCHEMBL29352376 0.86 KDM4E (1.00) KDM4EHSD17B10ALOX15TDP1MAPT
Methyldopa SCHEMBL34003 0.86 KDM4E (1.00) KDM4EHSD17B10ALOX15TDP1MAPT
Methyldopa SCHEMBL30176814 0.86 KDM4E (1.00) KDM4EHSD17B10ALOX15TDP1MAPT
SCHEMBL23754770 0.86 KDM4E (0.76) KDM4EHSD17B10ALOX15TDP1MAPT
SCHEMBL23754771 0.86 KDM4E (0.76) KDM4EHSD17B10ALOX15TDP1MAPT
Methyldopa SCHEMBL1172822 0.86 KDM4E (1.00) KDM4EHSD17B10ALOX15TDP1MAPT
Methyldopa (Racemic) SCHEMBL196981 0.86 KDM4E (1.00) KDM4EHSD17B10ALOX15TDP1MAPT
SCHEMBL29881977 0.86 KDM4E (0.76) KDM4EHSD17B10ALOX15TDP1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11702383-B2 Methods for producing D-α-methyldopa IMMUNOMOLECULAR THERAPEUTICS, INC. (US) 2023-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11702383-B2 Methods for producing D-α-methyldopa AMPD2, AMPD3, AMPD1 KDM4E 1719/4885HSD17B10 274/4885ALOX15 985/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.